TITLE

Apotex receives second FDA warning

AUTHOR(S)
Kondro, Wayne
PUB. DATE
June 2010
SOURCE
CMAJ: Canadian Medical Association Journal;6/15/2010, Vol. 182 Issue 9, pE421
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a reprint of the article "Apotex receives second FDA warning," by Wayne Kondro, which appeared between April 20 and May 18, 2010 at the web site www.cmaj.ca. It says that the U.S. Food and Drug Administration (FDA) had issued a second warning letter to Apotex Inc., a manufacturer of generic drugs, for failing good manufacturing practices. It adds that the new warning letter considers violations uncovered during FDA inspection such as the contamination of diabetes drug.
ACCESSION #
52224150

 

Related Articles

  • CNS News Round-Up.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p2 

    Reports on developments related to the pharmaceutical industry as of October 2003. Move of Novartis AG to license Cytos Biotechnology's Immunodrugs against Alzheimer's disease; Approval from the U.S. Food and Drug Administration granted to GlaxoSmithKline PLC to expand the indications of Paxil...

  • FDA Issues a Final Guidance on "Good Reprint Practices.".  // Venulex Legal Summaries;2009 Q1, Special section p1 

    The article focuses on final guidelines on good reprint practices for drug and medical device makers issued by the U.S. Food and Drug Administration (FDA). It notes that the Reprint Guidance has been issued to address the lack of guidance concerning the dissemination of off-label information...

  • U.S. FDA Cites Apotex's Bangalore Drug Facility for Fraudulent Data. CLARKE, TONI // News India Times;6/27/2014, Vol. 45 Issue 26, p23 

    The article reports on the warning letter posted by the U.S. Food and Drug Administration (FDA) on its web site concerning the manipulation of laboratory data by the Indian subsidiary of Canadian drug company Apotex Inc. in Bangalore, India.

  • FDA ISSUES IMPORT ALERT ON APOTEX.  // Chemical Week;9/14/2009, Vol. 171 Issue 23, p53 

    The article reports on an import alert issued by the U.S. Food and Drug Administration (FDA) on two of Apotex facilities, a generic pharmaceuticals company based in Toronto, Ontario. According to Apotex, the alerts are in connection with the observations made after routine audits for products...

  • Apotex, GlaxoSmithKline In Generics Battle Over Paxil. Krause, Carey // Chemical Market Reporter;5/21/2001, Vol. 259 Issue 21, p12 

    Reports that Apotex Corp. is seeking an injunction against GlaxoSmithKline (GSK) PLC and the United States (U.S.) Food and Drug Administration over its bid to launch a generic version of Paxil, an anti-depressant. Paxil sales in the U.S. in 2000; Generic equivalent to GSK approved paroxetine...

  • Apotex.  // Chain Drug Review;9/29/2014, Vol. 36 Issue 15, p101 

    The article profiles Apotex Corp., the U.S. subsidiary of the largest Canadian-owned pharmaceutical company Apotex Inc., which has succcessfully secured the approval from the U.S. Food and Drug Administration (FDA) for its 250 abbreviated new drug applications (ANDAs).

  • Pharmaceutical Companies Make Headway With Biosimilars.  // Chain Drug Review;3/16/2015, Vol. 37 Issue 5, p92 

    The article reports that the U.S. Food & Drug Administration has approved the launch of the filgrastim Grastofil from Canadain drug company Apotex Inc. in cooperation with Intas Pharmaceuticals Ltd.

  • Washington letter.  // DCI;May95, Vol. 156 Issue 5, p8 

    Reports on the reactions of the drug industry analysts on the possible privatization of the Food and Drug Administration (FDA).

  • NEW DOSING STRENGTH.  // Drug Topics;11/17/2003, Vol. 147 Issue 22, p78 

    Reports that Ivax Laboratories has updated its packaging for Nasarel Nasal Spray to reflect the Food and Drug Administration-labeling change in the U.S.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics